Is there a role for immune and anti-inflammatory therapy in type 2 diabetes?

T. Sathyapalan, Stephen Atkin

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

There is a growing body of evidence to suggest that type 2 diabetes is associated with a generalised activation of the innate immune system, in which there is a chronic low-grade inflammation. Further evidence for roles of inflammation in type 2 diabetes comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1β (Interleukin 1 β) antagonism and salsalate (non-acetylated prodrug of salicylate) treatment. In this review, recent evidence implicating the pathological involvement of the immune system in type 2 diabetes is examined, together with the role of potential treatment modalities targeting the immune system in the management of type 2 diabetes.

Original languageEnglish
Pages (from-to)147-156
Number of pages10
JournalMinerva Endocrinologica
Volume36
Issue number2
Publication statusPublished - Jun 2011
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Anti-Inflammatory Agents
Immune System
Inflammation
Salicylates
Prodrugs
Biological Factors
Therapeutics
Interleukin-1
Cytokines
Glucose

Keywords

  • Adipokines
  • Cytokines
  • Diabetes mellitus
  • Inflammation
  • Type 2

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Is there a role for immune and anti-inflammatory therapy in type 2 diabetes? / Sathyapalan, T.; Atkin, Stephen.

In: Minerva Endocrinologica, Vol. 36, No. 2, 06.2011, p. 147-156.

Research output: Contribution to journalReview article

@article{408f87bd413747b0a281a3dbde68d26c,
title = "Is there a role for immune and anti-inflammatory therapy in type 2 diabetes?",
abstract = "There is a growing body of evidence to suggest that type 2 diabetes is associated with a generalised activation of the innate immune system, in which there is a chronic low-grade inflammation. Further evidence for roles of inflammation in type 2 diabetes comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1β (Interleukin 1 β) antagonism and salsalate (non-acetylated prodrug of salicylate) treatment. In this review, recent evidence implicating the pathological involvement of the immune system in type 2 diabetes is examined, together with the role of potential treatment modalities targeting the immune system in the management of type 2 diabetes.",
keywords = "Adipokines, Cytokines, Diabetes mellitus, Inflammation, Type 2",
author = "T. Sathyapalan and Stephen Atkin",
year = "2011",
month = "6",
language = "English",
volume = "36",
pages = "147--156",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Is there a role for immune and anti-inflammatory therapy in type 2 diabetes?

AU - Sathyapalan, T.

AU - Atkin, Stephen

PY - 2011/6

Y1 - 2011/6

N2 - There is a growing body of evidence to suggest that type 2 diabetes is associated with a generalised activation of the innate immune system, in which there is a chronic low-grade inflammation. Further evidence for roles of inflammation in type 2 diabetes comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1β (Interleukin 1 β) antagonism and salsalate (non-acetylated prodrug of salicylate) treatment. In this review, recent evidence implicating the pathological involvement of the immune system in type 2 diabetes is examined, together with the role of potential treatment modalities targeting the immune system in the management of type 2 diabetes.

AB - There is a growing body of evidence to suggest that type 2 diabetes is associated with a generalised activation of the innate immune system, in which there is a chronic low-grade inflammation. Further evidence for roles of inflammation in type 2 diabetes comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1β (Interleukin 1 β) antagonism and salsalate (non-acetylated prodrug of salicylate) treatment. In this review, recent evidence implicating the pathological involvement of the immune system in type 2 diabetes is examined, together with the role of potential treatment modalities targeting the immune system in the management of type 2 diabetes.

KW - Adipokines

KW - Cytokines

KW - Diabetes mellitus

KW - Inflammation

KW - Type 2

UR - http://www.scopus.com/inward/record.url?scp=79960633056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960633056&partnerID=8YFLogxK

M3 - Review article

C2 - 21519323

AN - SCOPUS:79960633056

VL - 36

SP - 147

EP - 156

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

IS - 2

ER -